Symbols / RNTX
RNTX Chart
About
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 31.54M |
| Enterprise Value | 72.50M | Income | -58.88M | Sales | — |
| Book/sh | 0.05 | Cash/sh | 0.15 | Dividend Yield | — |
| Payout | 0.00% | Employees | 11 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 25.53 | P/C | — |
| EV/EBITDA | -3.05 | EV/Sales | — | Quick Ratio | 0.70 |
| Current Ratio | 0.90 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.94 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 08:00 | ROA | -18.81% |
| ROE | -83.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.29M |
| Shs Float | 19.70M | Short Float | 1.67% | Short Ratio | 3.88 |
| Short Interest | — | 52W High | 2.40 | 52W Low | 1.02 |
| Beta | 1.54 | Avg Volume | 156.49K | Volume | 109.04K |
| Target Price | $10.00 | Recom | None | Prev Close | $1.20 |
| Price | $1.20 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.20
Latest analyst target
3. DCF / Fair value
$-8.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.20
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | down | Brookline Capital | Buy → Hold | — |
| 2025-09-22 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2025-08-19 | down | Brookline Capital | Buy → Hold | — |
- Will RNTX stock benefit from automation - Trade Entry Summary & Reliable Entry Point Trade Alerts - Naître et grandir Sat, 07 Mar 2026 09
- Experimental inhaled IPF drug resumes Phase 2 testing after FDA clearance - Stock Titan ue, 03 Mar 2026 13
- Rein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20 - Nasdaq ue, 30 Sep 2025 07
- $RNTX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative Mon, 03 Nov 2025 08
- Voss capital reports $127k Rein Therapeutics (NASDAQ:RNTX) purchase - Investing.com ue, 18 Nov 2025 08
- Rein Therapeutics Completes Private Placement of Notes - TipRanks Mon, 02 Mar 2026 11
- RNTX Jolted: Analyzing Stock Movement - StocksToTrade Mon, 03 Nov 2025 08
- Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire hu, 15 May 2025 07
- Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing - Yahoo Finance Wed, 30 Jul 2025 07
- Rein Therapeutics Announces Immediate Board Director Resignation - TipRanks hu, 19 Feb 2026 08
- Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Mon, 03 Nov 2025 19
- Rein Therapeutics ends agreements with Yorkville, incurs no penalties - Investing.com hu, 11 Dec 2025 08
- RNTX Stock Price and Chart — NASDAQ:RNTX - TradingView Mon, 13 Jan 2025 20
- Rein Therapeutics secures third $1 million advance from Yorkville under financing deal - Investing.com Fri, 24 Oct 2025 07
- Brookline Capital Markets upgrades Rein Therapeutics stock rating to Buy - Investing.com Mon, 03 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 104183 | 127593 | — | Purchase at price 1.22 per share. | VOSS CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-14 00:00:00 | I |
| 1 | 306050 | 423466 | — | Purchase at price 1.37 - 1.39 per share. | VOSS CAPITAL, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-28 00:00:00 | I |
| 2 | 306050 | 423466 | — | Purchase at price 1.37 - 1.39 per share. | VOSS CAPITAL, LP | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-28 00:00:00 | I |
| 3 | 400 | 898 | — | Purchase at price 2.24 - 2.25 per share. | WINDSOR JAMES BRIAN | Chief Executive Officer | — | 2024-12-05 00:00:00 | I |
| 4 | 6607 | 21568 | — | Sale at price 3.25 - 3.30 per share. | UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | — | 2024-06-17 00:00:00 | D |
| 5 | 24671 | 80710 | — | Sale at price 3.25 - 3.35 per share. | UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | — | 2024-06-12 00:00:00 | D |
| 6 | 12315 | 40528 | — | Sale at price 3.25 - 3.30 per share. | UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | — | 2024-06-07 00:00:00 | D |
| 7 | 31151 | 139103 | — | Sale at price 4.10 - 5.02 per share. | UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-01 00:00:00 | D |
| 8 | 20315 | 85473 | — | Sale at price 4.10 - 4.32 per share. | UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -881.09K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.02 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 8.65M | -14.50M | -27.48M | -26.48M |
| TotalUnusualItems | -36.70M | -728.00K | 0.00 | 400.00K |
| TotalUnusualItemsExcludingGoodwill | -36.70M | -728.00K | 0.00 | 400.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -62.88M | -15.73M | -27.33M | -26.16M |
| ReconciledDepreciation | 63.00K | 119.00K | 169.00K | 121.00K |
| EBITDA | -28.05M | -15.23M | -27.48M | -26.48M |
| EBIT | -28.11M | -15.35M | -27.65M | -26.61M |
| NetInterestIncome | 400.00K | 400.00K | 300.00K | |
| InterestIncome | 400.00K | 400.00K | 300.00K | |
| NormalizedIncome | -27.06M | -15.00M | -27.33M | -26.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -62.88M | -15.73M | -27.33M | -26.16M |
| TotalExpenses | 28.11M | 15.35M | 27.65M | 26.61M |
| TotalOperatingIncomeAsReported | -65.11M | -16.28M | -27.65M | -26.61M |
| DilutedAverageShares | 17.94M | 4.60M | 4.54M | 4.44M |
| BasicAverageShares | 17.94M | 4.60M | 4.54M | 4.44M |
| DilutedEPS | -3.51 | -3.42 | -6.02 | -5.89 |
| BasicEPS | -3.51 | -3.42 | -6.02 | -5.89 |
| DilutedNIAvailtoComStockholders | -62.88M | -15.73M | -27.33M | -26.16M |
| NetIncomeCommonStockholders | -62.88M | -15.73M | -27.33M | -26.16M |
| NetIncome | -62.88M | -15.73M | -27.33M | -26.16M |
| NetIncomeIncludingNoncontrollingInterests | -62.77M | -15.68M | -27.33M | -26.16M |
| NetIncomeContinuousOperations | -62.77M | -15.68M | -27.33M | -26.16M |
| TaxProvision | -1.54M | 0.00 | ||
| PretaxIncome | -64.31M | -15.68M | -27.33M | -26.16M |
| OtherIncomeExpense | -36.60M | -728.00K | 318.00K | 441.00K |
| OtherNonOperatingIncomeExpenses | 100.00K | 318.00K | 441.00K | |
| SpecialIncomeCharges | -37.00M | -928.00K | 0.00 | 400.00K |
| GainOnSaleOfPPE | 100.00K | |||
| OtherSpecialCharges | -300.00K | |||
| ImpairmentOfCapitalAssets | 37.00M | 0.00 | ||
| RestructuringAndMergernAcquisition | 0.00 | 928.00K | 0.00 | |
| GainOnSaleOfSecurity | 300.00K | 200.00K | ||
| NetNonOperatingInterestIncomeExpense | 400.00K | 400.00K | 300.00K | |
| InterestIncomeNonOperating | 400.00K | 400.00K | 300.00K | |
| OperatingIncome | -28.11M | -15.35M | -27.65M | -26.61M |
| OperatingExpense | 28.11M | 15.35M | 27.65M | 26.61M |
| ResearchAndDevelopment | 14.25M | 3.99M | 17.97M | 17.01M |
| SellingGeneralAndAdministration | 13.86M | 11.36M | 9.68M | 9.60M |
| GeneralAndAdministrativeExpense | 13.86M | 11.36M | 9.68M | 9.60M |
| OtherGandA | 8.40M | 8.63M | 6.61M | 9.60M |
| SalariesAndWages | 5.46M | 2.72M | 3.07M | |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 21.67M | 4.89M | 4.54M | 4.53M |
| ShareIssued | 21.67M | 4.89M | 4.54M | 4.53M |
| TotalDebt | 0.00 | 48.00K | 33.00K | 162.00K |
| TangibleBookValue | -39.14M | -78.64M | 18.62M | 43.90M |
| InvestedCapital | 9.39M | 6.89M | 18.62M | 43.90M |
| WorkingCapital | 7.91M | 13.88M | 18.49M | 43.67M |
| NetTangibleAssets | -39.14M | -78.64M | 18.62M | 43.90M |
| CapitalLeaseObligations | 0.00 | 48.00K | 33.00K | 162.00K |
| CommonStockEquity | 9.39M | 6.89M | 18.62M | 43.90M |
| TotalCapitalization | 9.39M | 6.89M | 18.62M | 43.90M |
| TotalEquityGrossMinorityInterest | 9.39M | 6.89M | 18.62M | 43.90M |
| StockholdersEquity | 9.39M | 6.89M | 18.62M | 43.90M |
| GainsLossesNotAffectingRetainedEarnings | -18.00K | -63.00K | -48.00K | -13.00K |
| OtherEquityAdjustments | -18.00K | -63.00K | -48.00K | -13.00K |
| RetainedEarnings | -351.40M | -288.52M | -272.79M | -245.46M |
| AdditionalPaidInCapital | 360.70M | 295.38M | 291.37M | 289.28M |
| CapitalStock | 108.00K | 91.00K | 91.00K | 91.00K |
| CommonStock | 108.00K | 91.00K | 91.00K | 91.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 52.80M | 99.12M | 3.38M | 4.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 47.05M | 94.74M | 0.00 | 69.00K |
| OtherNonCurrentLiabilities | 277.00K | |||
| PreferredSecuritiesOutsideStockEquity | 45.01M | 91.41M | 0.00 | |
| NonCurrentDeferredLiabilities | 1.77M | 3.33M | 0.00 | |
| NonCurrentDeferredTaxesLiabilities | 1.77M | 3.33M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 69.00K | ||
| LongTermCapitalLeaseObligation | 0.00 | 69.00K | ||
| CurrentLiabilities | 5.75M | 4.38M | 3.38M | 4.51M |
| OtherCurrentLiabilities | 122.00K | 206.00K | 181.00K | 60.00K |
| CurrentDebtAndCapitalLeaseObligation | 48.00K | 33.00K | 93.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 48.00K | 33.00K | 93.00K |
| PayablesAndAccruedExpenses | 5.63M | 4.13M | 3.17M | 4.36M |
| CurrentAccruedExpenses | 4.72M | 2.94M | 1.45M | 3.15M |
| Payables | 911.00K | 1.19M | 1.72M | 1.21M |
| AccountsPayable | 911.00K | 1.19M | 1.72M | 1.21M |
| TotalAssets | 62.19M | 106.01M | 22.01M | 48.48M |
| TotalNonCurrentAssets | 48.53M | 87.74M | 134.00K | 304.00K |
| OtherNonCurrentAssets | 2.00K | 53.00K | 24.00K | 24.00K |
| NonCurrentPrepaidAssets | 0.00 | 2.14M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 48.53M | 85.53M | 0.00 | |
| OtherIntangibleAssets | 42.20M | 79.20M | ||
| Goodwill | 6.33M | 6.33M | 0.00 | |
| NetPPE | 1.00K | 19.00K | 110.00K | 280.00K |
| AccumulatedDepreciation | -358.00K | -270.00K | -212.00K | |
| GrossPPE | 377.00K | 380.00K | 492.00K | |
| OtherProperties | 152.00K | |||
| MachineryFurnitureEquipment | 377.00K | 340.00K | 340.00K | |
| BuildingsAndImprovements | 0.00 | 40.00K | 152.00K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 13.66M | 18.27M | 21.87M | 48.18M |
| OtherCurrentAssets | 676.00K | 721.00K | 606.00K | 2.22M |
| RestrictedCash | 0.00 | 25.00K | 25.00K | 25.00K |
| PrepaidAssets | 116.00K | 207.00K | 0.00 | 2.22M |
| CashCashEquivalentsAndShortTermInvestments | 12.87M | 17.31M | 21.24M | 45.93M |
| OtherShortTermInvestments | 0.00 | 16.05M | 42.33M | |
| CashAndCashEquivalents | 12.87M | 17.31M | 5.19M | 3.60M |
| CashEquivalents | 10.88M | 10.32M | 1.66M | |
| CashFinancial | 1.99M | 6.99M | 3.53M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -22.29M | -19.81M | -24.86M | -23.91M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 10.64M | 0.00 | 0.00 | 55.58M |
| CapitalExpenditure | -157.00K | |||
| EndCashPosition | 12.87M | 17.34M | 5.22M | 3.62M |
| BeginningCashPosition | 17.34M | 5.22M | 3.62M | 7.64M |
| EffectOfExchangeRateChanges | 0.00 | -63.00K | 0.00 | |
| ChangesInCash | -4.47M | 12.18M | 1.59M | -4.01M |
| FinancingCashFlow | 17.82M | 15.79M | 0.00 | 55.66M |
| CashFlowFromContinuingFinancingActivities | 17.82M | 15.79M | 0.00 | 55.66M |
| NetOtherFinancingCharges | 15.79M | |||
| ProceedsFromStockOptionExercised | 7.17M | 0.00 | 0.00 | 74.00K |
| NetCommonStockIssuance | 10.64M | 0.00 | 0.00 | 55.58M |
| CommonStockIssuance | 10.64M | 0.00 | 0.00 | 55.58M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 0.00 | 16.20M | 26.46M | -35.92M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 16.20M | 26.46M | -35.92M |
| NetInvestmentPurchaseAndSale | 0.00 | 16.25M | 26.46M | -35.83M |
| SaleOfInvestment | 0.00 | 16.25M | 48.31M | 37.75M |
| PurchaseOfInvestment | 0.00 | -21.85M | -73.58M | |
| NetBusinessPurchaseAndSale | 0.00 | -96.00K | 0.00 | |
| PurchaseOfBusiness | 0.00 | -96.00K | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | 42.00K | 0.00 | -91.00K |
| SaleOfPPE | 0.00 | 42.00K | 0.00 | 66.00K |
| PurchaseOfPPE | 0.00 | -157.00K | ||
| OperatingCashFlow | -22.29M | -19.81M | -24.86M | -23.75M |
| CashFlowFromContinuingOperatingActivities | -22.29M | -19.81M | -24.86M | -23.75M |
| ChangeInWorkingCapital | 2.41M | -5.38M | 420.00K | 242.00K |
| ChangeInOtherWorkingCapital | -1.55M | |||
| ChangeInOtherCurrentLiabilities | 229.00K | -65.00K | -129.00K | -66.00K |
| ChangeInOtherCurrentAssets | 2.19M | -3.00K | 0.00 | -24.00K |
| ChangeInPayablesAndAccruedExpense | 1.41M | -5.36M | -1.06M | 623.00K |
| ChangeInAccruedExpense | 1.69M | -382.00K | -1.57M | 1.01M |
| ChangeInPayable | -279.00K | -4.98M | 510.00K | -386.00K |
| ChangeInAccountPayable | -279.00K | -4.98M | 510.00K | -386.00K |
| ChangeInPrepaidAssets | 134.00K | 51.00K | 1.61M | -291.00K |
| StockBasedCompensation | 1.12M | 1.19M | 2.08M | 2.26M |
| AssetImpairmentCharge | 37.00M | 0.00 | ||
| AmortizationOfSecurities | 0.00 | 32.00K | -208.00K | 240.00K |
| DepreciationAmortizationDepletion | 63.00K | 119.00K | 169.00K | 121.00K |
| DepreciationAndAmortization | 63.00K | 119.00K | 169.00K | 121.00K |
| OperatingGainsLosses | -36.00K | -453.00K | ||
| GainLossOnSaleOfPPE | 0.00 | -36.00K | 0.00 | -66.00K |
| NetIncomeFromContinuingOperations | -62.88M | -15.73M | -27.33M | -26.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RNTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|